Precigen Inc PGEN 深 沪
已收盘 02-06 16:00:00 美东时间
4.29
+0.050
+1.18%
华盛通- 最 高4.46
- 今 开4.28
- 成交量 384.38万股
- 最 低 4.28
- 昨 收 4.24
- 总市值 15.18亿
- 52周最高 5.225
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 1.11
- 委 比 78.01%
- 总股本 3.54亿
- 历史最高 69.2096
- 量 比 1.23
- 振 幅 4.25%
- 历史最低 0.6513
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precigen Provides Update On Therapy For Recurrent Respiratory Papillomatosis, To Present Data At J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today provided an update on the
01-12 21:17
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points ...
2025-12-29 23:30
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Precigen’s Optimistic Earnings Call Highlights Papcemias Success
Precigen, Inc. (($PGEN)) has held its Q3 earnings call. Read on for the main hi...
2025-11-15 08:28
Vaxart, Precigen among biotech gainers after Q3 results
Shares of oral vaccine developer Vaxart (OTC:VXRT) and immunotherapy maker Precigen (PGEN) surged on Friday after the two biotechs posted strong topline beats with their Q3 2025 financials. San Franci...
2025-11-15 03:06
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $9
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $8.5 to $9.
2025-11-14 21:00
Precigen Q3 EPS $(1.06) Misses $(0.10) Estimate, Sales $2.922M Beat $500.000K Estimate
Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.10) by 1015.79 percent. This is a 1077.78 percent decrease over losses of $(0.09) per share from
2025-11-14 05:12
Precigen Reports Responses to PAPZIMEOS in Adults With Recurrent Respiratory Papillomatosis, Reinforcing FDA Approval
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term follow-up data demonstrating durable
2025-10-13 19:12
Precigen Converts Preferred Stock to Common Shares
An announcement from Precigen ( ($PGEN) ) is now available. On September 15, 20...
2025-09-18 05:18
Precigen announces up to $125M non-dilutive financing
Precigen (NASDAQ:PGEN) said on Wednesday that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors. The credit facility provides Precigen with up to $12...
2025-09-03 19:45
